The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The continued importance of reducing disparities in access to novel therapies for patients with NDMM
In this video, Hamlet Gasoyan, PhD, Cleveland Clinic, Cleveland, OH, briefly discusses the significance of findings from a study evaluating survival outcomes among black patients with newly diagnosed multiple myeloma (NDMM) in the era of novel therapies. As outcomes between black and white patients were comparable when access to therapies was equal, this highlights the importance of continued health equity interventions aimed at reducing disparities in access to novel therapies for minority populations. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Why are results important? So this tells us that our health equity interventions that are aimed to improve access in minority patients to myeloma therapies, they work. They can address the long-standing disparities when it comes to overall survival. So this gives us confirmation that what we are doing works. And also it’s very timely because as you will hear from this Congress, there has been an incredible progress in the availability of therapies for multiple myeloma...
Why are results important? So this tells us that our health equity interventions that are aimed to improve access in minority patients to myeloma therapies, they work. They can address the long-standing disparities when it comes to overall survival. So this gives us confirmation that what we are doing works. And also it’s very timely because as you will hear from this Congress, there has been an incredible progress in the availability of therapies for multiple myeloma. And, you know, when you have improvement in, you know, how you address the tumor, you got to note, you also have to remember that patients who need the therapies have equal access. So I think that it’s very timely and it just shows us that we’ve got to continue the work we are doing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
